终于有国产CAR-T企业快要扭亏了

Core Viewpoint - Legend Biotech's CAR-T therapy, Carvykti, is showing significant commercial success, particularly in the U.S. market, with a reported revenue of $1.888 billion in 2025, marking a 95.9% increase from the previous year [3][4]. Group 1 - Carvykti is the first Chinese-origin CAR-T therapy approved for use in the U.S., having received approval in February 2022 [3]. - The cumulative number of patients treated with Carvykti has surpassed 10,000, indicating strong market penetration [3]. - The production facility for Carvykti in Raritan, U.S., is now the largest cell therapy manufacturing site in the country [3]. Group 2 - Legend Biotech holds 70% rights for Carvykti in Greater China and 50% rights in Europe, the U.S., and Japan, following a global collaboration agreement with Johnson & Johnson's Janssen in December 2017 [4]. - In 2025, Carvykti's revenue in the U.S. reached $1.493 billion, accounting for nearly 80% of its total revenue, highlighting the therapy's reliance on the U.S. market [4]. - Despite being approved in China, Carvykti has not yet commenced commercial sales in the Chinese market, and its pricing in the U.S. is significantly higher than that of CAR-T therapies available in China [4].